ZA95628B - Preparation of recombinant adeno-associated viruses (aavs) and their use - Google Patents

Preparation of recombinant adeno-associated viruses (aavs) and their use

Info

Publication number
ZA95628B
ZA95628B ZA95628A ZA95628A ZA95628B ZA 95628 B ZA95628 B ZA 95628B ZA 95628 A ZA95628 A ZA 95628A ZA 95628 A ZA95628 A ZA 95628A ZA 95628 B ZA95628 B ZA 95628B
Authority
ZA
South Africa
Prior art keywords
pct
associated viruses
aavs
preparation
recombinant adeno
Prior art date
Application number
ZA95628A
Other languages
English (en)
Inventor
Vincent Descamps
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA95628B publication Critical patent/ZA95628B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA95628A 1994-01-28 1995-01-26 Preparation of recombinant adeno-associated viruses (aavs) and their use ZA95628B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9400934A FR2716682B1 (fr) 1994-01-28 1994-01-28 Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.

Publications (1)

Publication Number Publication Date
ZA95628B true ZA95628B (en) 1995-10-23

Family

ID=9459501

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95628A ZA95628B (en) 1994-01-28 1995-01-26 Preparation of recombinant adeno-associated viruses (aavs) and their use

Country Status (17)

Country Link
US (1) US5789390A (de)
EP (1) EP0741793B1 (de)
JP (1) JP3810078B2 (de)
KR (1) KR100403708B1 (de)
AT (1) ATE310097T1 (de)
AU (1) AU706647B2 (de)
CA (1) CA2181602A1 (de)
DE (1) DE69534618T2 (de)
DK (1) DK0741793T3 (de)
ES (1) ES2252738T3 (de)
FI (1) FI962990L (de)
FR (1) FR2716682B1 (de)
IL (1) IL112461A0 (de)
MX (1) MX9603002A (de)
NO (1) NO319885B1 (de)
WO (1) WO1995020671A1 (de)
ZA (1) ZA95628B (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
FR2738575B1 (fr) * 1995-09-08 1997-10-10 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US6207457B1 (en) * 1995-09-08 2001-03-27 Avigen, Inc. Targeted nucleotide sequence delivery and integration system
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
EP0928202A4 (de) * 1996-09-25 2001-09-05 Cell Genesys Inc Nicht-invasive verabreichung von adeno-assoziierten viralen vektoren
WO1998027204A2 (en) * 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US20040161409A1 (en) * 1997-07-25 2004-08-19 Kurtzman Gary J. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
JP4220125B2 (ja) * 1997-12-03 2009-02-04 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 高い比活性を有するエリスロポエチン
DE19830141A1 (de) * 1998-07-06 2000-01-13 Regine Heilbronn Rekombinante Herpesviren für die Erzeugung rekombinanter Adeno-Assoziierter-Viren
US6303362B1 (en) * 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
DE19905501B4 (de) * 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20040043488A1 (en) * 1999-02-17 2004-03-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Adeno-associated viral gene-transfer vector system
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US7208315B2 (en) 2000-01-05 2007-04-24 Fred Hutchinson Cancer Research Center Compositions and methods for efficient AAV vector production
US6965010B2 (en) * 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
IL155154A0 (en) * 2000-09-30 2003-10-31 Diversa Corp Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
EP1427816A4 (de) 2001-09-18 2004-12-01 Clontech Lab Inc Auf stellenspezifischer rekombinase beruhendes verfahren zur herstellung von adenovirusvektoren
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
CA2485341A1 (en) * 2002-05-08 2004-06-17 Intronn, Inc. Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
CA2503247A1 (en) * 2002-10-23 2004-05-06 Intronn, Inc. Screening methods for identification of efficient pre-trans-splicing molecules
US20050120398A1 (en) * 2003-09-12 2005-06-02 Vertex Pharmaceuticals Incorporated Animal model for HCV infection
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
CA2553828A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7582442B2 (en) * 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
EP1755400A2 (de) * 2004-06-18 2007-02-28 The University Of Montana Aav-vermittelte genabgabe an kochlearzellen
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
FI20050753A7 (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
WO2006083331A2 (en) * 2004-10-08 2006-08-10 Intronn, Inc Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
WO2006091722A2 (en) * 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
DE602006020881D1 (de) 2005-08-15 2011-05-05 Vegenics Pty Ltd Enen eigenschaften
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
CA2633468C (en) 2005-12-14 2014-02-18 Licentia Ltd Novel neurotrophic factor protein and uses thereof
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2010002895A2 (en) 2008-06-30 2010-01-07 The Regents Of The University Of Michigan Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
AU2012255143A1 (en) 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
DK2785683T3 (da) 2011-11-30 2020-04-14 Ludwig Inst For Cancer Res Ltd Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
DK2892617T3 (en) 2012-09-06 2018-09-03 Univ Chicago ANTISENSE POLYNUCLEOTIDES FOR INDUCTION OF EXON SKIPPING AND PROCEDURES FOR TREATING DYSTROPHIES
SMT202000088T1 (it) 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
SI3283500T1 (sl) 2015-04-08 2020-12-31 The University Of Chicago Sestavki in postopki za popravilo medenično ramenske distrofije tipa 2C z uporabo preskakovanja eksonov
JP7405434B2 (ja) 2018-06-11 2023-12-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド ストレス関連障害および癌を治療するための材料および方法
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors

Also Published As

Publication number Publication date
EP0741793B1 (de) 2005-11-16
DE69534618D1 (de) 2005-12-22
EP0741793A1 (de) 1996-11-13
FI962990A0 (fi) 1996-07-26
IL112461A0 (en) 1995-03-30
ATE310097T1 (de) 2005-12-15
FI962990A7 (fi) 1996-07-26
DE69534618T2 (de) 2006-07-27
MX9603002A (es) 1997-06-28
FR2716682B1 (fr) 1996-04-26
DK0741793T3 (da) 2006-03-27
AU1539595A (en) 1995-08-15
JPH09509051A (ja) 1997-09-16
WO1995020671A1 (fr) 1995-08-03
JP3810078B2 (ja) 2006-08-16
FI962990L (fi) 1996-07-26
CA2181602A1 (fr) 1995-08-03
NO962950D0 (no) 1996-07-12
AU706647B2 (en) 1999-06-17
FR2716682A1 (fr) 1995-09-01
KR100403708B1 (ko) 2004-05-31
US5789390A (en) 1998-08-04
NO319885B1 (no) 2005-09-26
ES2252738T3 (es) 2006-05-16
NO962950L (no) 1996-07-12

Similar Documents

Publication Publication Date Title
IL112461A0 (en) Preparation of recombinant adeno-associated viruses (aavs) and their use
ATE362542T1 (de) Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
DE69739860D1 (de) Rekombinante AAV zur Herstellung eines Medikaments für die Gentherapie von Muskelzellen
CA2187626A1 (en) Aav-mediated delivery of dna to cells of the nervous system
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
PL331005A1 (en) Regulating dna of hamster's ef-1alpha transcription
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
DK1783225T3 (da) Strukturprotein fra AAV, dets fremstilling og anvendelse
DE69635931D1 (de) Komplementäre adenovirenvektorsysteme und zellinien
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
GR3035050T3 (en) Method of preparing a viral vector by homologous intermolecular recombination
EP0696206A4 (de) Adenoviren mit veränderten faserproteinen
WO1998028317A3 (en) Synthesis of nucleosides and polynucleotides
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
CA2199832A1 (en) Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
IL131014A0 (en) Methods for cultivating cells and propagating viruses
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
ZA958128B (en) Viral vectors and use in gene therapy
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
PL320481A1 (en) Composition for treating creatine substances, containing at least one grafted silicone polymer of polysiloxane skeleton grafted with organic non-silicone monomers and at least one anionic polymer
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
HU9601298D0 (en) Endothelin-converting enzyme
WO1999025814B1 (en) Genetically-modified myogenic progenitors and their use in cell and gene therapy
AU2620595A (en) Recombinant viruses, preparation and use thereof in gene therapy
WO1999053959A3 (en) Use of viral vectors for treatment of the injured peripheral and central nervous system